Reported 2 days ago
A recent bullish thesis on Harmony Biosciences Holdings, Inc. (HRMY) highlights its investment potential due to its flagship product, WAKIX, which treats narcolepsy without the addictive risks of competitors. Despite setbacks such as a short-seller claim and clinical study failures, Harmony's strong financials project increasing sales, with management targeting over $1 billion by 2027. The company's low valuation relative to its growth prospects suggests significant upside potential, making it an interesting option for investors amidst the biotech landscape.
Source: YAHOO